Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
, 125 (2), 247-257

A Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Trial of Creatine Monohydrate as Adjunctive Treatment for Bipolar Depression

Affiliations
Randomized Controlled Trial

A Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Trial of Creatine Monohydrate as Adjunctive Treatment for Bipolar Depression

Ricardo Alexandre Toniolo et al. J Neural Transm (Vienna).

Abstract

Depressive episodes are a major cause of morbidity and dysfunction in individuals suffering from bipolar disorder. Currently available treatments for this condition have limited efficacy and new therapeutic options are needed. Extensive research in the pathophysiology of bipolar disorder points to the existence of mitochondrial and bioenergetic dysfunction. We hypothesized that creatine monohydrate, a nutraceutical that works as a mitochondrial modulator, would be effective as an adjunctive therapy for bipolar depression. We conducted a double-blind trial in which 35 patients with bipolar disorder type I or II in a depressive episode by DSM-IV criteria and in use of regular medication for the treatment of this phase of the disease were randomly allocated into two adjunctive treatment groups for 6 weeks: creatine monohydrate 6 g daily (N = 17) or placebo (N = 18). Primary efficacy was assessed by the change in the Montgomery-Åsberg Depression Rating Scale (MADRS). We did not find a statistically significant difference in the comparison between groups for the change in score on the MADRS after 6 weeks in an intention-to-treat (ITT) analysis (p = 0.560; Cohen's d = 0.231). However, we found significant superiority of creatine add-on vs. placebo when we considered the remission criterion of a MADRS score ≤ 12 at week 6 analyzing the outcome of the 35 randomized patients on ITT (52.9% remission in the creatine group vs. 11.1% remission in the placebo group) and of the 23 completers (66.7% remission in the creatine group vs. 18.2% remission in the placebo group) (p = 0.012; OR = 9.0 and p = 0.036; OR = 9.0, respectively). Two patients who received creatine switched to hypomania/mania early in the trial. No clinically relevant physical side-effects were reported or observed. This proof-of-concept study, aiming to restore brain bioenergetics using an adjunctive mitochondrial modulator, is not conclusive on the efficacy of creatine add-on for bipolar depression, but suggests that this compound may have a role in the adjunctive treatment of this phase of the illness. Further investigation through randomized controlled trials with larger samples should be conducted to verify the efficacy of creatine supplementation for bipolar depression and also for subsyndromal depressive symptoms.

Trial registration: ClinicalTrials.gov NCT01655030.

Keywords: Adjunctive therapy; Bipolar disorder; Creatine monohydrate; Depression; Double-blind method; Randomized controlled trial.

Conflict of interest statement

RA.T., M.S., F.B.F.F., J.A.M.S.A., R.S.D. and B.L. report no potential conflicts of interest.

Figures

Fig. 1
Fig. 1
Screening, randomization and disposition of 35 patients with bipolar depression assigned to adjunctive treatment with creatine monohydrate or placebo
Fig. 2
Fig. 2
Observed and last observation carried forward Montgomery–Åsberg Depression Rating Scale (MADRS) scores at each treatment week for 27 patients with bipolar depression assigned to a 6-week adjunctive treatment with creatine monohydrate or placebo

Similar articles

See all similar articles

Cited by 1 PubMed Central articles

  • Creatine for the Treatment of Depression
    BM Kious et al. Biomolecules 9 (9). PMID 31450809. - Review
    Depressed mood, which can occur in the context of major depressive disorder, bipolar disorder, and other conditions, represents a serious threat to public health and well …

References

    1. Allen PJ, D’Anci KE, Darrell C, Galinko L, Salvatore J, Kanarek RB, Renshaw PF (2010) Creatine supplementation offsets depressive behavior in female rats independent of fluoxetine. In: Society for Neuroscience 40th annual meeting, San Diego
    1. Bartoli F, Dell’Osso B, Crocamo C, Fiorillo A, Ketter TA, Suppes T, Clerici M, Carrà G. Benefits and harms of low and high second-generation antipsychotics doses for bipolar depression: a meta-analysis. J Psychiatr Res. 2017;88:38–46. doi: 10.1016/j.jpsychires.2016.12.021. - DOI - PubMed
    1. Bauer M, Glenn T, Conell J, Rasgon N, Marsh W, Sagduyu K, et al. Common use of dietary supplements for bipolar disorder: a naturalistic, self-reported study. Int J Bipolar Disord. 2015;3(1):29. - PMC - PubMed
    1. Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008;64(6):468–475. doi: 10.1016/j.biopsych.2008.04.022. - DOI - PubMed
    1. Brown NC, Andreazza AC, Young LT. An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res. 2014;218(1–2):61–68. doi: 10.1016/j.psychres.2014.04.005. - DOI - PubMed

Publication types

Associated data

Feedback